A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
NCT00163111
Last updated date
ABOUT THIS STUDY
This is a study to investigate the safety and efficacy of voriconazole for the treatment of
candidemia in critically ill non-neutropenic patients
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Candidiasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Patients with candidemia
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Neutropenia
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
CandidiasisStudy Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
NCT00496197
- Birmingham, Alabama
- Birmingham, Alabama
- Little Rock, Arkansas
- Los Angeles, California
- San Francisco, California
- San Francisco, California
- Newark, Delaware
- Newark, Delaware
- Wilmington, Delaware
- Washington, District of Columbia
- Jacksonville, Florida
- Miami, Florida
- Orlando, Florida
- Orlando, Florida
- Orlando, Florida
- Atlanta, Georgia
- Springfield, Illinois
- Springfield, Illinois
- Springfield, Illinois
- Springfield, Illinois
- Baltimore, Maryland
- Baltimore, Maryland
- Detroit, Michigan
- Detroit, Michigan
- Royal Oak, Michigan
- Minnesota, Minnesota
- Butte, Montana
- Camden, New Jersey
- Albany, New York
- Buffalo, New York
- Rochester, New York
- Greenville, North Carolina
- Greenville, North Carolina
- Portland, Oregon
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- West Reading, Pennsylvania
- Charleston, South Carolina
- Houston, Texas
- Seoul,
- Seoul,
- Seoul,
- Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
CandidiasisThe Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)
NCT00041704
- King of Prussia, Pennsylvania
ALL GENDERS
12 Years+
years
MULTIPLE SITES
CandidiasisEarly Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
NCT01202253
- London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
CandidiasisA Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
NCT01092832
- Wuhan, Hubei
- Beijing,
- Brno,
- Hong Kong,
- Hong Kong,
- Shatin, N.T.,
- Budapest,
- Budapest,
- Budapest,
- Colonia Insurgentes Cuicuilco, Delegacion Coyoacan, DF
- Ermita,, Manila
- Manila,
- Olsztyn,
- Bratislava,
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. | |||
| Official Title ICMJE | A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects. | |||
| Brief Summary | This is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Candidiasis | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 412 | |||
| Original Enrollment ICMJE | 400 | |||
| Actual Study Completion Date ICMJE | May 2003 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 70 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00163111 | |||
| Other Study ID Numbers ICMJE | 608 A1500608 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | April 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||